Meta Health (SGX:5DX) has signed a non-binding term sheet to acquire up to 30% of Aios Bio Sciences, a medical device company, according to a Wednesday filing on the Singapore Exchange.
The deal may also involve a larger stake. Payment could be made through the issuance of new shares in Meta Health, subject to due diligence and further negotiations.
The acquisition aims to diversify Meta Health's business into medical consumables and point-of-care diagnostics. The transaction is contingent on due diligence, board approval, and a 60-day exclusivity period.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。